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Microfluidic blood plasma separation for medical
diagnostics: is it worth it?
W. S. Mielczarek,ab E. A. Obaje,b T. T. Bachmannb and M. Kersaudy-Kerhoas*ab
Circulating biomarkers are on the verge of becoming powerful diagnostic tools for various human diseases.
However, the complex sample composition makes it difficult to detect biomarkers directly from blood at
the bench or at the point-of-care. Blood cells are often a source of variability of the biomarker signal.
While the interference of hemoglobin is a long known source of variability, the release of nucleic acids and
other cellular components from hemocytes is a new concern for measurement and detection of circulat-
ing extracellular markers. Research into miniaturised blood plasma separation has been thriving in the last
10 years (2006–2016). Most point-of-care systems need microscale blood plasma separation, but devel-
oped solutions differ in complexity and sample volume range. But could blood plasma separation be
avoided completely? This focused review weights the advantages and limits of miniaturised blood plasma
separation and highlights the most interesting advances in direct capture as well as smart blood plasma
separation.
1 Introduction
Human plasma is the most important and one of the most
convenient sources of circulating biomarkers. Studies on
plasma proteome, transcriptome and metabolome have rap-
idly increased the spectrum of diagnostic targets for a wide
range of diseases from cancer1 to Alzheimer's2 to sepsis.3
Likewise, antibodies as well as foreign nucleic acids and anti-
gens present in plasma, allow for the diagnosis of serious in-
fectious diseases such as those caused by Ebola4 or Zika5 vi-
ruses during recent outbreaks.
The quality of biomarkers often depends not only on bio-
logical factors such as physical condition and age of the pa-
tient, but also on technical factors such as the lack of
standardisation of sample collection and preparation.6–8
Amongst other technical factors, in vitro hemolysis is a well-
known source of biomarker variability. Blood cells such as
leukocytes, or white blood cells, can also be a source of con-
tamination in relation to biomarkers such as cell-free DNA
targets. Therefore, plasma separation from hemocytes is very
desirable in most cases. In the lab-on-a-chip community, a
growing number of groups are tackling the challenge of
micro-scale blood plasma separation (BPS), with often good
results in yield or purity, but rarely achieving both at the
same time. Recent lab-on-chip (LOC) developments, which
demonstrate some level of sample preparation and/or detec-
tion of circulating blood biomarkers, still omit the blood
plasma separation part. In a large number of cases, the oper-
ator of the LOC relies on a bench-top centrifuge to produce
plasma as the input sample even if the required volume is in
the range of a few microlitres. Therefore, continuing im-
provement of microscale blood plasma separation seems
needed to achieve truly integrated and point-of-care (POC) de-
vices. However, given the complexity of microscale plasma
separation, could this step be avoided altogether? The im-
provements in direct capture now allow some circulating bio-
markers to be detected in the blood matrix, allowing “sample
preparation free” solutions. Is microfluidic blood plasma sep-
aration still worth it? Could it really be integrated on-chip or
could it be achieved with a centrifuge next to a point-of-care
testing (POCT) device?
A review we published in 2013 produced a detailed map of
the miniaturised blood plasma separation state-of-the-art, list-
ing and describing analytes of interest, characterisation and
the challenges of blood plasma separation at the microscale.9
Tripathi et al. recently reviewed the design rules of passive
blood plasma separation techniques.10 Here we provide a
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balanced overview of miniaturised blood plasma separation
by considering the arguments for omitting integrated BPS in
POC devices as well as highlighting the most interesting ad-
vances in the field between 2013 and 2016.
2 Avoiding blood plasma separation:
rationale and solutions
The main rationale for avoiding BPS arises from the short-
comings of currently available BPS technologies.10,11 These
shortcomings are (i) inconsistencies with diluting blood sam-
ples; as observed in the literature, majority of the POC sys-
tems require dilution of whole blood which introduces inac-
curacies into the measurements and reduced concentration
of target analytes, subsequently leading to reduced assay sen-
sitivity. (ii) Complex designs that are cost-ineffective to inte-
grate into microfluidic platforms; these tend to be a feature
of active BPS techniques which generally involve the use of
external force fields for separation. (iii) Time consuming
workflow systems with low extraction rates; these tend to be
associated with passive BPS systems that rely solely on the
properties of blood flow at the microscale, leading to poten-
tial low throughput and slow flow rates.
To alleviate the aforementioned issues, recent technologi-
cal advances have led to the development of simplified
microfluidic systems that facilitate biomarker detection di-
rectly from whole blood samples, thereby bypassing the need
for on/off-chip BPS and its inherent complexities. Examples
of these novel POC systems can be broadly categorised
according to the factors that have made direct detection of
analytes from whole blood possible.
Improvements in analyte characterisation and analyte-
capture technology
Exhaustive research into understanding and characterising
analyte binding efficiencies has facilitated the development
of novel immunoassay capture strategies directly from whole
blood.12,13 For example, extensive research into cardiac
markers (analytes) like troponin and N-terminal pro b-type
natriuretic peptide (NT-proBNP) have led to the development
of commercially available POC assays like the Radiometer
AQT90 FLEX analyser, a 20 minute BPS-free sandwich immu-
noassay test directly from 2 mL of blood for effective cardio-
vascular diagnosis and treatment.14 Additionally, better char-
acterisation of genomic marker sequences has led to
optimised molecular diagnostic assays. As an example, the
mitochondrial cytochrome oxidase subunit 1 gene is targeted
in an isothermal amplification assay (loop-mediated isother-
mal amplification (LAMP)) for malarial DNA from a sample
of heat-treated host's blood without nucleic acid purification
in about 30 minutes (∼1 parasite per μL blood). This assay is
capable of distinguishing P. falciparum from P. vivax15
confirming the obvious benefits of improved analyte charac-
terisation by increased knowledge of target sequences.
Improvements in signal transduction and amplification
mechanisms
Coupling the advances in analyte capture technology with in-
novative signal transduction and amplification strategies has
enabled the development of new POCTs bypassing BPS. For
example, an integrated, multiplexed digital-analogue micro-
fluidic immunoassay platform based on the principles of me-
chanically induced trapping of molecular interactions
(MITOMI),16 used for enhanced monitoring of binding affini-
ties of molecular interactions like protein-antibody has re-
cently been validated for rapid, specific and sensitive (100
pM) detection of anti-Ebola IgG in ultralow volume of whole
blood samples (5 μL). The dynamic range of the immuno-
assay was significantly enhanced by combining digital
MITOMI (i.e. enzyme conjugated) with analogue MITOMI
(fluorophore-labelled) readout systems. Subsequently a low-
cost portable prototype system was capable of sensitively
distinguishing between three common Ebola strains in a
multiplexed assay format.17
Novel microfluidic composite material
Advances in the development of composite materials for
microfluidic devices have led to improved platforms for
immobilising capture probes. An affordable enzyme-linked
immunosorbent assay (ELISA) test for the prostate-specific
antigen (PSA) tumour marker normally performed on stan-
dard microtiter plates (MTP), was ported successfully onto a
POC device utilising a melt-extruded fluoropolymer micro-
capillary film (MCF) for sensitive, direct and affordable whole
blood PSA screening in low resource settings. The new PSA
MCF ELISA was shown to be 20 times faster than the stan-
dard MTP ELISA, whilst maintaining similar assay perfor-
mance with respect to precision and limit of detection
(LoD).18,19
Alternative strategies
The developments of novel nanoparticle-based bioassays are
also lending themselves to providing suitable BPS-free POC
solutions that can overcome the matrix effects of whole blood
coupled with inexpensive readout systems based on common
consumer electronics. For example, a POCT was recently
constructed to sensitively detect thrombin activity at 18 NIH
units per mL in 12 μL of blood (by monitoring hydrolase ac-
tivity), using an integration of immobilised semiconductor
quantum dots (QD) and Förster resonance energy transfer
(FRET) with a smartphone imaging readout on a paper-in-
PDMS chip. The system was further adapted for sensitive
streptavidin detection (200 nM–10 μM) from 50% whole
blood, via a competitive binding assay highlighting its poten-
tial for detecting multiple protein analyte classes while using
common consumer electronics as a viable POC diagnostic
platform.20
Some of the example assays mentioned above still need
to be optimised before being adapted into commercially
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available POCTs. However, it is becoming more evident that
rapid technological advances are leading to increasing num-
ber of sensitive, smart and simplified POCT examples
bypassing BPS, hence creating a rationale for its exclusion.
3 Blood plasma separation: when and
why do you need it?
With both established and novel biomarkers, reproducibility
and accuracy of the analytical methods are paramount. How-
ever, the quality of the analytical methods does not always
guarantee the diagnostic usefulness of the test. An important
yet sometimes overlooked issue relates to variabilities in sam-
ple collection, storage and processing. Indeed, preanalytical
variables are recognised as the predominant source of mis-
takes in laboratory medicine, accounting for up to 70% of
all laboratory errors.21 Therefore, the need for improving
preanalytical procedures has been highlighted in a number
of publications reviewing diagnostic methods.22 As described
in the previous section, diagnostic tests are being successfully
designed for the direct detection of biomarkers in blood, re-
moving the need for integrating BPS in POCTs. However, the
presence of blood cells in the sample disrupts the detection
of a range of biomarkers in a number of ways. We review
some of these effects.
Influence of hemolysis in blood samples
The breakdown of erythrocyte (red blood cells) membranes
causing the release of hemoglobin in blood in- or ex vivo is a
leading problem during the preanalytical phase. in vitro he-
molysis in laboratory samples accounts for up to 40–70% of
sample rejections in laboratories, and has a direct financial
impact.23,24 The variability of microRNA levels due to hemoly-
sis has been well documented.25 Not all, but a large fraction
of microRNAs identified so far are affected by sample han-
dling.26 As illustrated in Fig. 1, Kirschner et al. have shown
that the levels of miRNA are affected even by low hemolysis,
typically undetectable by eye, and thus difficult to systemati-
cally exclude through a simple visual inspection.25 Proteins
are also affected by hemolysis. An important example regards
the use of cardiac troponins I (cTnI) and T (cTnT) to diag-
nose acute myocardial infarction and other cardiac diseases.
cTnI and cTnT have been used in POC tests directly on blood
samples as detailed in the previous sections and have been
reported to be unaffected by moderate hemolysis.27 However,
a study by Bais using a different cTn assay has shown that
hemolysis index of around 150 (hemoglobin concentration of
1.9 g L−1) caused a 20% change in cTn, above the critical
level, suggestive of an acute myocardial infarction.28 Al-
though these examples relate to extreme physiological condi-
tions rather than common cases, they highlight the advan-
tage of rapidly obtaining hemolysis-free samples.29,30
The third example of the influence of hemolysis on circu-
lating biomarkers relates to metabolites. Hemolysis can
falsely decrease or increase values of metabolites, like potas-
sium, lactate dehydrogenase, and aspartate aminotransfer-
ase.31 In particular, potassium concentration in RBCs is over
20 times that of plasma, making it notoriously sensitive to
hemolysis.31 It was shown that over a third of hypokalemic
cases (potassium deficiency) could be missed due to hemoly-
sis when using whole blood to estimate potassium level.29
The elevation of potassium due to hemolysis has been
reported to be more important in capillary blood samples
compared to venous blood samples, which is of special
interest to POCT applications.32 It was also shown that tem-
perature during transport might lead to misdiagnosis and
“pseudo hyperkalemia”, or so-called “seasonal pseudo-
hyperkalemia”.33 To alleviate this issue, a study showed that
the introduction of centrifuges in UK GP surgeries led to a
reduction of these cases, thereby proving the benefits of
rapid, point-of-care plasma extraction.34 While temperature
control during sample transport might be possible in some
cases, the universal removal of blood cells prior to transport
is an attractive idea. We have discussed the impact of hemo-
lysis on various important and common diagnostic tests.
However, it is important to note that not all analytes are
sensitive to hemolysis and a number of them can withstand
delayed plasma separation for several days without changing
significantly (less than 4% per day).35
Influence of leukolysis
Leukocytes lysis, or leukolysis, also has significant effects on
circulating biomarkers, specifically molecular markers, in
situations where the released background genomic DNA acts
as noise on the molecular marker signal. This situation is
specifically encountered in non-invasive, nucleic-acid-based
cancer and prenatal diagnostic. A low concentration of cell-
free DNA (cfDNA), around 10–50 ng ml−1, is normally detect-
able in plasma from healthy subjects prepared by standard
Fig. 1 Paired hemolysed and non-hemolysed samples from four pa-
tients (coded MM1, MM2, CAD1, N1) showing different levels of two
microRNAs (hsa-miR-451 and hsa-miR-16) commonly used as refer-
ence genes in microRNA assays. Reproduced from ref. 25 under Crea-
tive Commons Attribution (CC BY) license.
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centrifugation (1600g), representing hundreds or thousands
of genome copies per ml. In the case of prenatal diagnos-
tics, fetal DNA is thought to make up typically 10–15% of
the total circulating DNA, depending strongly on gestation
age and perinatal health.36,37 Fluctuations in the detectable
fetal nucleic acid fraction can be attributed to the release of
maternal DNA during maternal cell lysis. Extracting plasma
at the site of blood draw has been shown to efficiently elimi-
nate the contamination from maternal cells.38 Similarly, can-
cer tumours lead to the presence of free circulating tumour
DNA (ctDNA) which can be used for early cancer diagnostic
and treatment monitoring. However, the abundance of geno-
mic DNA dilutes the tumour derived ctDNA and hinders ro-
bust detection of mutations.39 In both of these applications,
pre-analytical factors such as the rapid removal or the
stabilisation of blood cells have been shown to improve the
reliability of the detection.40
Microfluidics, an attractive technology to standardise the
preanalytical phase
Physical cell preservation solutions do not alleviate sample
preparation and introduce an additional cost on top of the
total sample preparation cost (individual commercial cell
stabilisation tubes generally cost above $6). While hemolysis
due to delayed blood preparation constitutes only a fraction
of all in vitro hemolysis cases, in general, miniaturised,
microfluidic-based solutions for blood plasma sample prepa-
ration at the site of blood draw might help to standardise the
preparation through robust near-patient solutions, decreas-
ing the variability of biomarker measurements. In several of
the cases presented earlier, plasma extraction at the site of
blood draw has been shown to effectively remove detrimental
blood cell contamination. At present, regardless of the re-
quired sample volume, plasma is obtained from whole blood
using a centrifuge that has a significant footprint, needs
batch-processing and might not always be available. Inte-
grated sample preparation and in particular the removal of
blood cells needed for the reliable detection of circulating
biomarkers, remain a bottleneck in the development of a
number of POC devices. In the next section, we look at the
most recent solutions with a focus on performance factors
such as plasma recovery. Table 1 provides a summary of the
advantages and limitations of the two approaches.
4 Separation strategies
The number and type of tests to perform dictates the volume
of plasma required, and subsequently the starting volume of
blood. For example, in monitoring chronic hepatitis B pa-
tients 6 to 8 tests are typically performed with a requirement
of at least 200 μL of plasma in total,41 while measurements
on circulating nucleic acid can require as much as several
millilitres of plasma.42 Here we classify the techniques by
processed sample volume to offer clarity to end-users looking
for the most suitable approaches (Table 2).
4.1 Finger-prick volumes up to a few microlitres
Many diagnostic tests such as blood gas, electrolytes and me-
tabolites (BGEM) tests can be carried out on plasma from a
drop of blood,43 enabling traditional venepuncture to be
substituted with a finger-prick procedure, an important asset
in POC setting. Filtration and paper-based technologies are a
common approach when working with blood volumes in the
microlitre range. Kim et al. developed a filtration-based tool
for separating 2.5 μl of plasma in 3 min and its subsequent
deposition on a collection disc, which can be air-dried and
sent for analysis. Measurements of vitamin D and spiked-in
yeast enolase revealed that the extracted plasma was equiva-
lent to the venepuncture-derived control.44 Other filtration
methods required blood dilution to increase filter life-
time.45,46 Kuo et al. tested a capillary-driven chip, in which
cells are eliminated through size-exclusion. Plasma can be
extracted in 75 s from 10 μl of whole blood at 15% yield
through a fishbone microchannel network.47 Another capil-
lary driven chip with filtering microstructures was capable of
extracting 0.1 μl plasma from 5 μl of undiluted blood.48 Re-
cent developments in centrifugal disc (CD) microfluidic sys-
tems, or so called lab-on-a-disc systems, allowed for separa-
tion of plasma from undiluted blood and achieved highly
controlled actuation of small sample volumes, which is re-
quired for integrated analyte detection. The disc is spun on a
rotating platform and separation was achieved within a few
seconds,49 while other systems typically removed 99.5% of
cells in 10 min.50
Separation of plasma from microlitre amounts of
undiluted blood was also achieved by methods ranging from
capillary chip with asymmetric superhydrophilic coating,51 to
cotton thread,52 to phase-guide assisted sedimentation53 and
Table 1 Opportunities and limitations of plasma extraction by centrifugation and microfluidic approaches
Centrifugation Microfluidic based techniques
Advantages • High yield • Can be integrated with continuous flow processes
• High purity depending on parameters • Standardisation possible
• Reproducible • Portable
• Well established • Contained
Limits • Batch-processing • New method, lack of reproducibility studies
• Bulky • Variable efficiencies
• Relatively expensive • Low yield
• Potential for low-cost
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to dielectrophoresis (DEP).54,55 Different levels of blood dilu-
tion were needed for systems based on sedimentation (1 : 3
(ref. 56) and 1 : 9 (ref. 57)), magnetophoresis (1 : 10)58 and a
combination of hydrodynamic separation with DEP (1 : 1).59
4.2 Finger-prick or venous blood volumes in the microlitre
range
It is worth mentioning that even if the blood volume needed
for the test is between 1 μl and several hundred microlitres it
does not imply that capillary blood can be used. As levels of
analytes can be different in capillary and venous blood, for
some tests microlitre blood volume will still be collected
through venepuncture.60 Recent advancements in processing
blood samples of volumes up to a few hundred microlitres
have been achieved with membrane filtration, passive hydro-
dynamic separation, centrifugal microfluidics and active sep-
aration methods. A centrifugal system for liver function
screening at resource poor settings separates plasma from
150 μl of capillary blood and performs a 5-parameter liver as-
say panel in less than 20 min.61 Liu et al. demonstrated a de-
vice in which up to 200 μl of undiluted blood is sandwiched
between two superhydrophobic surfaces. The device is left for
10 min allowing the cells to settle down and plasma to fill a
collection chamber through a membrane placed at the top of
the blood reservoir. Yield of 33% is achieved and 85% recov-
ery of spiked-in S. mansoni genomic DNA was demon-
strated.62 An electrochemical paper-based analytical device
(ePAD) using blood separation paper (VF2, Whatman) was de-
veloped by Noiphung et al. Plasma from 250 μl of undiluted
blood was separated in 4 min and subsequently the glucose
level was measured.63 An unorthodox approach was employed
by Kim and Choi who created hand-held “smart-pipette” with
a microfluidic plasma separating tip relying on hydro-
phoresis. A 5 min operation produced 60 μl of plasma with
93% separation efficiency.64 A capillary driven chip with low-
voltage (1 V) DEP for capturing RBCs from 150 μl undiluted
blood was developed by Chen et al. The device was capable of
removing close to 90% of RBCs with around 40% volumetric
plasma yield. However, the removal efficiency of WBCs and
platelets were not measured.65
4.3 Venous blood volumes in the millilitre range
When processing large blood volumes, avoiding the satura-
tion issues encountered in filtration is crucial, and this has
been traditionally achieved by hydrodynamic plasma separa-
tion, a method employed in the seminal work of Yang et al.66
The most widely used systems rely on plasma skimming ef-
fect sometimes referred to as the Zweifach–Fung effect.9
Plasma is extracted in a channel bifurcation through a side
channel of higher fluidic resistance while cells flow through
a main, low resistance channel. Usually the separation is en-
hanced by additional geometrical features like constriction–
expansion regions improving both the cell focussing and
plasma skimming effects. This approach requires external
pumping equipment but often achieves high throughputs.
However, the usual trade-off is high blood dilution (typically
1 : 1 to 1 : 20). Agarwal and co-workers published several pa-
pers exploring the impact of different bifurcation geometries,
Table 2 Plasma analytes and extraction methods with the corresponding typical blood sample volumes. Figures adapted from references (from left to
right): 44 with the permission of the American Chemical Society, 62 with the permission of the Royal Society of Chemistry and 67 with the permission
of Springer
Blood volumes
Finger-prick volumes up to a few
microlitres
Finger-prick or venous blood volumes
in the microlitre range
Venous blood volumes in the
millilitre range
Typical plasma analytes Blood gas, electrolytes and
metabolites (BGEM)
BGEM Protein and peptide markers
Protein markers Protein and peptide markers Antigens
Antigens Antigens Circulating nucleic acids (CNAs)
Pathogenic DNA/RNA Pathogenic DNA/RNA
microRNA Illegal drugs and their metabolites
Microfluidic plasma
separation methods
Filtration Filtration-based High-throughput hydrodynamic
Sedimentation Centrifugal (CD) Sedimentation–filtration
Centrifugal (CD) Hydrophoresis
Capillary hydrodynamic Dielectrophoresis
Active methods
Examples of technology
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e.g. varying constriction length and bend, on plasma
extraction.67–70 In the recent work chips were tested at a wide
range of hematocrits (7–62%) achieving separation efficiency
close to 100% and plasma quality was validated by measuring
levels of glucose and human chorionic gonadotropin (hCG)
hormone. Although plasma yield was rather low (1–6%), the
devices could potentially produce a few hundreds of micro-
litres of plasma due to relatively high throughputs (0.3–0.5
ml min−1) with reported reduced clogging.68 Marchalot et al.
developed a BPS platform with two constriction–expansion
units placed in series. The group studied the effect of system
geometry on development of cell free layer and cell-focussing
at relatively high dilutions (1 : 10–1 : 20). Numerical calcula-
tions of their network's hydraulic resistance helped to reach
a 25% volumetric extraction yield of highly diluted plasma
with a purity of 99% or higher.71 Others have tried to vary the
constriction geometry to enhance the formation of a micro-
vortex, with limited success (1 : 20 blood dilution, separation
efficiency 90%).72
Inertial microfluidics, developed for cell sorting73 have
been applied to separate plasma from blood. Cell removal
through inertial focussing with secondary flow has been
achieved in a constriction–expansion array74 and serpentine
channel.75,76 The last device, comprised of 16 multiplexed
slanted spiral channels, achieved a particularly high separa-
tion efficiency of 100% at yield close to 50% and massive
throughput of 24 ml min−1. However, the system is only suit-
able for highly diluted blood (Hct = 0.5–1%).76 The limiting
factor is the interaction between cells, that was found to pre-
vent cell focussing at Hct higher than several percent.75
Commercially available plasma separating membranes, al-
though predominantly aimed at microlitre blood volumes,
have also been used for large sample volumes. Liu et al. de-
veloped a hybrid sedimentation–filtration based system, in
which plasma is extracted on 2 sides of a vertical sample
loading chamber. Filter clogging was largely reduced through
gravitational sedimentation of cells and the device was capa-
ble of extracting 275 μl of plasma from 1.8 ml undiluted
blood (yield 15%). The group used HIV-spiked blood to evalu-
ate device's utility in diagnostics.77 In another sedimenta-
tion–filtration device, blood is drawn through a cell sedimen-
tation chamber with an additional microporous membrane
at the end, producing plasma of ∼99% purity. The sedimen-
tation chamber requires priming with isotonic buffer that
leads to some plasma dilution (generally lower than 1 : 1).78
Gong et al. developed a simple cartridge PMMA based device
capable of filtering plasma out of millilitre volumes of blood
through a membrane. Sample flow was improved by hydro-
philic coating of the channels. In ∼5 min the device pro-
duced over 100–200 μl of plasma from 0.8–1 ml of blood
achieving remarkable separation efficiency of 99.9% and
96.9% for RBCs and WBCs, respectively. The group tested
the device in POC setting, performing a number of hepati-
tis B related tests on clinical samples, achieving results
similar to those based on control plasma obtained by
centrifugation.41
5 Recommendations and future
outlook
In a large number of cases, plasma provides a stable matrix
for the detection of analytes and biomarkers susceptible to
hemo- and leukolysis, making miniaturised plasma extrac-
tion especially attractive for POCT. In parallel, researchers
continue to pursue the refinement of strategies aimed at re-
moving the need for blood plasma separation altogether.
Here we reviewed some technological considerations and po-
tential challenges for the development of microfluidic BPS
technologies.
Solving the dilution issue
Methods where high blood dilution is needed have arguable
applicability in medical diagnostics. A hypothetical efficient
pump-operated device (25% plasma yield, 30 ml h−1 inlet flow
rate) separating plasma from blood diluted 1 : 10 requires 30
min to extract a sample volume containing only 200 μl of
undiluted plasma. Based on a 45% Hct the dilution of such
plasma sample is approximately 1 : 18, which can make the
detection of rare analytes difficult or impossible. Further-
more, considering major progress in effective self-driven low-
impact solutions for extracting the same volumes of
undiluted plasma, the development of high throughput sys-
tems should demonstrate production of plasma samples suit-
able for diagnostics purposes.
Technological considerations
Medical diagnostics could potentially benefit from stand-
alone microfluidic plasma extraction at the point of blood
draw, as it has the potential to circumvent issues around the
transport of blood in the context of circulating molecular
markers detection. For example, we have demonstrated the
use of stand-alone plasma separation in the specific context
of prenatal diagnostics,79 while others proposed a BPS device
producing plasma-bearing strips ready for transport.44 Inte-
gration of BPS modules into full LOC is nevertheless impor-
tant for the reasons listed in section 3.
There is no single best microfluidic BPS technology, with
each one having its advantages and limitations. In general,
hybrid devices presented here achieved higher yield and sam-
ple purity than those employing a single separation mecha-
nism.77,78 Therefore, a hybrid approach, in which advantages
of different BPS mechanisms are combined in one device,
has a large potential in plasma-based POC diagnostics, espe-
cially for processing larger volumes of blood. An inherent is-
sue of all microfluidic technologies relates to clogging. While
it is most apparent in filter-based devices (finite lifetime lim-
iting sample volume processed), larger microfluidic channels
can also get clogged from cell aggregation, coagulation or
presence of debris. In order for a BPS technology to be con-
sidered for product development, it needs to produce both
high quality plasma sample and demonstrate reliability. For
this reason, information on device failure rate would
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contribute to assessing the efficacy of the method. Moreover,
the practicality of a particular solution strongly depends on
fabrication. The use of complex fabrication methods and de-
signs as well as the use of external equipment for device op-
eration should be justified by improvements in performance.
Additionally, compatibility with mass fabrication methods is
crucial for translation to market.
Suitability of the extracted plasma for diagnostic purpose
The majority of papers presenting BPS do not include a com-
prehensive study of plasma quality such as remaining cell
content and hemolysis measurements. For instance, flow cy-
tometry, automated hemocytometry or manual cell counting
can be used for measuring residual cell content in plasma
but have different precision, and comparison of results
obtained with different methods is not always informative.
Demonstration of successful biomarker detection enables the
evaluation of the device for a specific diagnostic purpose, but
the lack of a robust generic biological characterisation hin-
ders conclusive comparison of the available technologies.
Therefore, we recommend that more rigorous testing is car-
ried out to assess the performance of new devices in the con-
text of medical diagnostics.
Acknowledgements
WSM is funded by a James Watt Scholarship. MKK acknowl-
edges the Royal Academy of Engineering for funding.
Notes and references
1 G. Cheng, Adv. Drug Delivery Rev., 2015, 81, 75–93.
2 B. Olsson, R. Lautner, U. Andreasson, A. Öhrfelt, E.
Portelius, M. Bjerke, M. Hölttä, C. Rosén, C. Olsson, G.
Strobel, E. Wu, K. Dakin, M. Petzold, K. Blennow and H.
Zetterberg, Lancet Neurol., 2016, 15, 673–684.
3 S. Neugebauer, E. J. Giamarellos-Bourboulis, A. Pelekanou,
A. Marioli, F. Baziaka, I. Tsangaris, M. Bauer and M. Kiehntopf,
Crit. Care Med., 2016, DOI: 10.1097/CCM.0000000000001740.
4 WHO Public report for RealStar® Filovirus Screen RT-PCR
Kit 1.0 (EA 0002-002-00), 2014.
5 R. Charrel, I. Leparc-Goffart and S. Pas, Bull. W. H. O.,
2016, DOI: 10.2471/BLT.16.171207.
6 K. W. Witwer, E. I. Buzás, L. T. Bemis, A. Bora, C. Lässer, J.
Lötvall, E. N. N.-‘t Hoen, M. G. Piper, S. Sivaraman, J. Skog,
C. Théry, M. H. Wauben and F. Hochberg, J. Extracell.
Vesicles, 2013, 2.
7 L. H. Araujo, C. Timmers, K. Shilo, W. Zhao, J. Zhang, L. Yu,
T. G. Natarajan, C. J. Miller, A. S. Yilmaz, T. Liu, J. Amann,
J. R. Lapa E Silva, C. G. Ferreira and D. P. Carbone, PLoS
One, 2015, 10, e0143092.
8 H. Butz and A. Patócs, Exper. Suppl., 2015, 106, 55–71.
9 M. Kersaudy-Kerhoas and E. Sollier, Lab Chip, 2013, 13,
3323–3346.
10 S. Tripathi, Y. V. B. Varun Kumar, A. Prabhakar, S. S. Joshi,
A. Agrawal, Y. V. B. V. Kumar, A. Prabhakar, S. S. Joshi and
A. Agrawal, J. Micromech. Microeng., 2015, 25, 083001.
11 D. Gossett, W. Weaver and A. Mach, Anal. Bioanal. Chem.,
2010, 397(8), 3249–3267.
12 P. B. Luppa, C. Müller, A. Schlichtiger and H. Schlebusch,
TrAC, Trends Anal. Chem., 2011, 30, 887–898.
13 P. von Lode, Clin. Biochem., 2005, 38, 591–606.
14 B. T. Ivandic, E. Spanuth and E. Giannitsis, Clin. Lab.,
2014, 60, 903–908.
15 S. S. Modak, C. A. Barber, E. Geva, W. R. Abrams, D.
Malamud and Y. S. Y. Ongagna, Infect. Dis., 2016, 9, 1–9.
16 J. L. Garcia-Cordero and S. J. Maerkl, J. Lab. Autom.,
2016, 21, 356–367.
17 F. Piraino, F. Volpetti, C. Watson and S. J. Maerkl, ACS
Nano, 2016, 10, 1699–1710.
18 A. I. Barbosa, A. P. Castanheira, A. D. Edwards and N. M.
Reis, Lab Chip, 2014, 14, 2918–2928.
19 B. Hallmark, F. Gadala-Maria and M. R. Mackley,
J. Nonnewton. Fluid Mech., 2005, 128, 83–98.
20 E. Petryayeva and W. R. Algar, Analyst, 2015, 140, 4037–4045.
21 M. Plebani, Clin. Chim. Acta, 2009, 404, 16–23.
22 P. Carraro, G. Servidio and M. Plebani, Clin. Chem., 2000, 46,
306–307.
23 G. Lippi, N. Blanckaert, P. Bonini, S. Green, S. Kitchen, V.
Palicka, A. J. Vassault and M. Plebani, Clin. Chem. Lab. Med.,
2008, 46(6), 764–772.
24 S. F. Green, Clin. Biochem., 2013, 46, 1175–1179.
25 M. B. Kirschner, S. C. Kao, J. J. Edelman, N. J. Armstrong, M. P.
Vallely, N. van Zandwijk and G. Reid, PLoS One, 2011, 6, e24145.
26 L. Moldovan, K. E. Batte, J. Trgovcich, J. Wisler, C. B. Marsh
and M. Piper, J. Cell. Mol. Med., 2014, 18, 371–390.
27 M. Daves, G. L. Salvagno, R. Cemin, M. Gelati, G. Cervellin,
G. C. Guidi and G. Lippi, Clin. Lab., 2012, 58, 333–336.
28 R. Bais, Clin. Chem., 2010, 56, 1357–1359.
29 R. C. Hawkins, Clin. Chem., 2003, 49, 1226–1227.
30 C. Puelacher, R. Twerenbold, T. Mosimann, J.
Boeddinghaus, M. Rubini Gimenez, K. Wildi, C. Jaeger, T.
Reichlin, J. Schneider, U. Honegger, W. Max, C.
Schumacher, T. Nestelberger, P. Hillinger, K. Grimm, P.
Kreutzinger, Z. Moreno Weidmann, K. Rentsch, C. Arnold, S.
Osswald and C. Mueller, Int. J. Cardiol., 2015, 187, 313–315.
31 J. R. Asirvatham, V. Moses and L. Bjornson, N. Am. J. Med.
Sci., 2013, 5, 255–259.
32 M. Oostendorp, W. W. van Solinge and H. Kemperman,
Arch. Pathol. Lab. Med., 2012, 136, 1262–1265.
33 D. Sinclair, J. Clin. Pathol., 2003, 56, 385–387.
34 H. E. Turner, R. W. A. Peake and J. J. Allison, Ann. Clin.
Biochem., 2012, 49, 94–96.
35 S. Clark, Clin. Chem., 2003, 49, 518–520.
36 A. B. Sparks, C. A. Struble, E. T. Wang, K. Song and A.
Oliphant, Am. J. Obstet. Gynecol., 2012, 206, 319.e1–319.e9.
37 G. E. Palomaki, E. M. Kloza, G. M. Lambert-Messerlian, J. E.
Haddow, L. M. Neveux, M. Ehrich, D. van den Boom, A. T.
Bombard, C. Deciu, W. W. Grody, S. F. Nelson and J. A.
Canick, Genet. Med., 2011, 13, 913–920.
Lab on a Chip Frontier
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
4/
10
/2
01
6 
15
:3
2:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
3448 | Lab Chip, 2016, 16, 3441–3448 This journal is © The Royal Society of Chemistry 2016
38 A. N. Barrett, H. A. Thadani, C. Laureano-Asibal, S.
Ponnusamy and M. Choolani, Prenatal Diagn., 2014, 34,
1283–1288.
39 X. Xue, M. D. Teare, I. Holen, Y. M. Zhu and P. J. Woll, Clin.
Chim. Acta, 2009, 404, 100–104.
40 J. L. Sherwood, C. Corcoran, H. Brown, A. D. Sharpe, M.
Musilova and A. Kohlmann, PLoS One, 2016, 11, e0150197.
41 M. M. Gong, B. D. MacDonald, T. Vu Nguyen, K. Van Nguyen
and D. Sinton, Biomicrofluidics, 2013, 7, 44111.
42 R. W. K. Chiu, R. Akolekar, Y. W. L. Zheng, T. Y. Leung, H.
Sun, K. C. A. Chan, F. M. F. Lun, A. T. J. I. Go, E. T. Lau,
W. W. K. To, W. C. Leung, R. Y. K. Tang, S. K. C. Au-Yeung,
H. Lam, Y. Y. Kung, X. Zhang, J. M. G. van Vugt, R.
Minekawa, M. H. Y. Tang, J. Wang, C. B. M. Oudejans, T. K.
Lau, K. H. Nicolaides and Y. M. D. Lo, BMJ, 2011, 342,
c7401.
43 Abaxis Inc., http://www.piccoloxpress.com/wp-content/
uploads/centrifugation-whitepaper.pdf.
44 J.-H. Kim, T. Woenker, J. Adamec and F. E. Regnier, Anal.
Chem., 2013, 85, 11501–11508.
45 J. Chen, D. Chen, T. Yuan, X. Chen, Y. Xie, H. Fu, D. Cui, X.
Fan and M. K. Khaing Oo, Microelectron. Eng., 2014, 128,
36–41.
46 J. H. Son, S. H. Lee, S. Hong, S. Park, J. Lee, A. M. Dickey
and L. P. Lee, Lab Chip, 2014, 14, 2287–2292.
47 J.-N. Kuo and Y.-H. Zhan, Microsyst. Technol., 2013, 21,
255–261.
48 M. Hojjat, C.-T. Jasmina and M. Mahdi, Biofabrication,
2015, 7, 25007.
49 J.-N. Kuo and X.-F. Chen, Microsyst. Technol., 2015, 22,
861–869.
50 Z. Cai, J. Xiang and W. Wang, Sens. Actuators, B, 2015, 221,
257–264.
51 K. K. Lee and C. H. Ahn, Lab Chip, 2013, 13, 3261–3267.
52 M. F. Ulum, L. Maylina, D. Noviana and D. H. B. Wicaksono,
Lab Chip, 2016, 1492–1504.
53 L. Xu, H. Lee, M. V. Brasil Pinheiro, P. Schneider, D. Jetta
and K. W. Oh, Biomicrofluidics, 2015, 9, 014106.
54 C. Szydzik, K. Khoshmanesh, A. Mitchell and C. Karnutsch,
Biomicrofluidics, 2015, 9, 64120.
55 S.-H. Liao, C.-Y. Chang and H.-C. Chang, Biomicrofluidics,
2013, 7, 24110.
56 C. Kuroda, Y. Ohki, H. Ashiba, M. Fujimaki, K. Awazu, T.
Tanaka and M. Makishima, in Proceedings of IEEE Sensors,
December 2014, vol. 2014-Decem, pp. 1854–1857.
57 Y. Xie, D. Chen, S. Lin, Z. Wang and D. Cui, RSC Adv.,
2016, 6, 30722–30727.
58 P. Kim, E. H. Ong, K. H. H. Li, Y.-J. Yoon, S. H. G. Ng and K.
Puttachat, Biomicrofluidics, 2016, 10, 24110.
59 M. Mohammadi, H. Madadi, J. Casals-Terré and J. Sellarès,
Anal. Bioanal. Chem., 2015, 407, 4733–4744.
60 Australian PoCT Practitioner's Network.
61 C. E. Nwankire, M. Czugala, R. Burger, K. J. Fraser, T. M.
O'Connell, T. Glennon, B. E. Onwuliri, I. E. Nduaguibe, D.
Diamond and J. Ducrée, Biosens. Bioelectron., 2014, 56,
352–358.
62 C. Liu, S.-C. Liao, J. Song, M. G. Mauk, X. Li, G. Wu, D. Ge,
R. M. Greenberg, S. Yang and H. H. Bau, Lab Chip, 2016, 16,
553–560.
63 J. Noiphung, T. Songjaroen, W. Dungchai, C. S. Henry, O.
Chailapakul and W. Laiwattanapaisal, Anal. Chim. Acta,
2013, 788, 39–45.
64 B. Kim and S. Choi, Small, 2016, 12, 190–197.
65 C.-C. Chen, P.-H. Lin and C.-K. Chung, Lab Chip, 2014, 14,
1996–2001.
66 S. Yang, A. Ündar and J. D. Zahn, Lab Chip, 2006, 6,
871–880.
67 A. Prabhakar, Y. V. B. V. Kumar, S. Tripathi and A. Agrawal,
Microfluid. Nanofluid., 2015, 18, 995–1006.
68 S. Tripathi, Y. V. B. Kumar, A. Agrawal, A. Prabhakar and
S. S. Joshi, Sci. Rep., 2016, 6, 26749.
69 S. Tripathi, A. Prabhakar, N. Kumar, S. G. Singh and A.
Agrawal, Biomed. Microdevices, 2013, 15, 415–425.
70 S. Tripathi, Y. V. B. Varun Kumar, A. Prabhakar, S. S. Joshi
and A. Agrawal, J. Micromech. Microeng., 2015, 25, 084004.
71 J. Marchalot, Y. Fouillet and J.-L. Achard, Microfluid.
Nanofluid., 2014, 17, 167–180.
72 A. Haller, A. Spittler, L. Brandhoff, H. Zirath, D. Puchberger-
Enengl, F. Keplinger and M. J. Vellekoop, Micromachines,
2015, 6, 239–251.
73 D. Di Carlo, Lab Chip, 2009, 9, 3038–3046.
74 M. G. Lee, J. H. Shin, S. Choi and J.-K. Park, Sens. Actuators,
B, 2014, 190, 311–317.
75 J. Zhang, S. Yan, W. Li, G. Alici and N.-T. Nguyen, RSC Adv.,
2014, 4, 33149–33159.
76 M. Rafeie, J. Zhang, M. Asadnia, W. Li and M. E. Warkiani,
Lab Chip, 2016, 16, 2791–2802.
77 C. Liu, M. Mauk, R. Gross, F. D. Bushman, P. H. Edelstein,
R. G. Collman and H. H. Bau, Anal. Chem., 2013, 85,
10463–10470.
78 C. Galligan, J. Nichols, E. Kvam, P. Spooner, R. Gettings, L.
Zhu and C. M. Puleo, Lab Chip, 2015, 15, 3274–3277.
79 M. Kersaudy-Kerhoas, M. Desmulliez and J. Norman, Arch.
Dis. Child. Fetal Neonatal Ed., 2014, 99, A2.
Lab on a ChipFrontier
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
1 
A
ug
us
t 2
01
6.
 D
ow
nl
oa
de
d 
on
 0
4/
10
/2
01
6 
15
:3
2:
00
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Online
